Dietary Supplement Disclaimer Requirements Under DSHEA

Supplement brands often focus on claim wording while overlooking procedural requirements. The disclaimer and notification rules are not optional formatting — they are statutory conditions for marketing structure/function statements on supplement labeling. FDA warning letters frequently cite missing or incorrect disclaimers alongside disease claims.

New SKUs, line extensions, and flavor variants each require a fresh look at disclaimer placement and notification status when structure/function language appears on the label. A parent brand may have notified FDA for an original formula, but a new claim on a reformulated product triggers a new 30-day notification obligation. Operations teams should flag label art changes to compliance before print runs.

What is the mandatory dietary supplement disclaimer?

The required disclaimer reads: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." It must appear on the label in boldface type, in a size no smaller than one-sixteenth inch (with limited exceptions for small packages). FDA structure/function claims guidance specifies disclaimer placement and notification procedures.

When is the disclaimer required?

The disclaimer is required when a supplement label bears a structure/function claim, a statement of general well-being from consumption of a nutrient, or a statement describing a benefit related to a nutrient deficiency disease (with additional conditions). Pure nutrient content claims or brand names without benefit statements may not trigger the disclaimer — but many supplement labels do include benefit language.

What is the 30-day FDA notification requirement?

The manufacturer, packer, or distributor must submit a notification to FDA with the text of the structure/function claim within 30 days of first marketing the product with that claim. Notification is submitted through FDA's structure/function claim notification process. Failure to notify is a separate violation from misbranding for missing disclaimers. FDA dietary supplement guidance includes resources on structure/function claims, labeling, and notification procedures.

Maintain internal records showing the notification date, claim text submitted, and responsible person who filed. If marketing adds a new structure/function statement to an existing label, treat it as a new claim requiring fresh notification — do not assume prior filings cover updated wording. See our guide on do supplement claims need FDA approval for how DSHEA procedural rules fit within the broader supplement regulatory framework.

Do disclaimers belong on websites and ads too?

The statutory disclaimer requirement applies to labeling. However, structure/function claims on websites and ads still must be truthful, substantiated, and must not cross into disease claims. Many brands voluntarily repeat the disclaimer on product pages for consistency. The FTC evaluates advertising substantiation regardless of FDA disclaimer placement on labels.

Amazon listings, influencer posts, and email campaigns that repeat structure/function language should stay within the same boundaries as the label. Disease-adjacent keywords in bullets — "joint pain relief," "blood sugar support" — may convert marketing into unapproved drug claims regardless of disclaimer presence on the physical label. Cross-channel consistency reduces both FDA misbranding risk and FTC substantiation exposure.

How do supplement disclaimers relate to disease claims?

The disclaimer does not make disease claims permissible. If marketing suggests the product treats arthritis, cancer, or COVID-19, FDA treats the product as an unapproved drug regardless of disclaimer presence. See our structure/function vs. disease claims guide for wording boundaries. Natascia Taken, Esq. reviews supplement copy for both claim category and DSHEA procedural compliance.

What labeling elements accompany the DSHEA disclaimer?

Beyond the disclaimer itself, supplement labels must include a Supplement Facts panel, ingredient list, net quantity, and name and place of business of the manufacturer, packer, or distributor. Structure/function claims should appear on labeling in a way that does not obscure required panels. Natascia Taken, Esq. recommends proofing final print files — not just copy documents — because disclaimer font size and boldface requirements are measured on the physical label.

Common dietary supplement disclaimer mistakes

• Using paraphrased disclaimer text instead of the exact statutory language on labels.
• Disclaimer font too small or not boldface on packaging.
• Adding structure/function claims at launch without submitting 30-day notification.
• Assuming the disclaimer protects against FTC substantiation scrutiny.
• Inconsistent claim language between label, Amazon listing, and influencer posts.

Quality teams and marketing teams should share a single changelog when structure/function statements are added, removed, or modified. FDA notification and disclaimer compliance are operational tasks that fail when label art updates bypass compliance review. Natascia Taken, Esq. often finds that the fastest path to a warning letter is a new marketing claim added to a website weeks before the updated label reaches warehouses.

See our guide on do supplement claims need FDA approval for how DSHEA fits within the broader question of pre-market review. Structure/function claims are permitted without FDA pre-approval when procedural requirements are satisfied — but disease claims remain impermissible regardless of disclaimer presence. Train customer service teams not to improvise benefit language in chat responses that contradict label claims or omit required context.